EFSA published on 30.03.2023 a Statement on a targeted risk assessment for famoxadone.
25th April 2023
EFSA Statement targeted assessment famoxadone
25April
13th January 2022
EFSA Art.12 review of novaluron
13January
On 13.01.2022 EFSA published an Article 12 review of the existing MRLs for novaluron.